I have a co-worker that repeatedly has an issue with including an Rh-control (i.e. 6% albumin) with AB,Rh-positive patients once it has been established on two different samples. My standpoint considering regulatory guidelines and product insert information is that when the ABO/Rh must be re-established on specimens used for transfusion purposes the Rh-control for AB, Rh-positive patients must be included to reflect the current serologial status of the patient. I would appreciate all input on how this testing aspect is perceived at other transfusion services. Thanks, Nick.
When clinically significant antibodies are detected during pretransfusion testing what specific standard requires notification to be given to the patient and should this notification be done by the patient's Physician or Transfusion Service. Any information will be appreciated. Thanks, Nick.